Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up
Autor: | Jan-Erik Palmgren, Vesa Kataja, Päivi Auvinen, K. Vuolukka, Sirpa Aaltomaa |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Neoplasms Radiation-Induced medicine.medical_treatment Brachytherapy lcsh:RC254-282 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Risk Factors Surgical oncology Internal medicine Genetics Humans Medicine Risk factor Finland Aged Retrospective Studies business.industry Subsequent primary cancer Incidence Incidence (epidemiology) Mortality rate Low dose-rate brachytherapy Prostatic Neoplasms Neoplasms Second Primary Radiotherapy Dosage Middle Aged Prognosis medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Low-Dose Rate Brachytherapy Radiation induced subsequent primary cancer Survival Rate Radiation therapy 030220 oncology & carcinogenesis business Follow-Up Studies Research Article |
Zdroj: | BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background As aging is the most significant risk factor for cancer development, long-term prostate cancer (PCa) survivors have an evident risk of developing subsequent primary cancers (SPCs). Radiotherapy itself is an additional risk factor for cancer development and the SPCs appearing beyond 5 years after radiotherapy in the original treatment field can be considered as radiation-induced subsequent primary cancers (RISPCs). Methods During the years 1999-2008, 241 patients with localized PCa who underwent low dose-rate brachytherapy (LDR-BT) with I125 and were followed-up in Kuopio University Hospital, were included in this study. In this study the incidences and types of SPCs and RISPCs with a very long follow-up time after LDR-BT were evaluated. Results During the median follow-up time of 11.4 years, a total of 34 (14.1%) patients developed a metachronous SPC. The most abundant SPCs were lung and colorectal cancers, each diagnosed in six patients (16.7% out of all SPCs). The crude incidence rate of RISPC was 1.7% (n = 4). Half of the SPC cases (50%) were diagnosed during the latter half of the follow-up time as the risk to develop an SPC continued throughout the whole follow-up time with the actuarial 10-year SPC rate of 7.0%. The crude death rates due to metachronous out-of-field SPCs and RISPCs were 50 and 50%, respectively. Conclusion The crude rate of SPC was in line with previously published data and the incidence of RISPC was very low. These results support the role of LDR-BT as a safe treatment option for patients with localized PCa. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |